Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation

•This retrospective analysis compared unmodified and CD34+ cell-selected allo-HSCT in MDS.•The composite endpoint of survival without relapse and without chronic GVHD was superior in the CD34+ cell-selected group.•Relapse is affected by high-risk cytogenetics, but not by type of transplant. In this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biology of blood and marrow transplantation 2018-05, Vol.24 (5), p.1079-1087
Hauptverfasser:	Tamari, Roni, Oran, Betul, Hilden, Patrick, Maloy, Molly, Kongtim, Piyanuch, Papadopoulos, Esperanza B., Rondon, Gabriela, Jakubowski, Ann A., Andersson, Borje S., Devlin, Sean M., Ahmed, Sairah, Popat, Uday R., Ponce, Doris, Chen, Julianne, Sauter, Craig, Young, James W., de Lima, Marcos, Perales, Miguel-Angel, O'Reilly, Richard J., Giralt, Sergio A., Champlin, Richard E., Castro-Malaspina, Hugo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Allogeneic transplantation Allografts - cytology Antigens, CD34 - blood Chromosome Aberrations Female Graft vs Host Disease - etiology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Humans Lymphocyte Depletion Male Middle Aged Myelodysplastic syndrome Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - mortality Myelodysplastic Syndromes - therapy Recurrence Risk Assessment Survival Analysis T cell depletion Transplantation, Homologous Treatment Outcome Unmodified
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•This retrospective analysis compared unmodified and CD34+ cell-selected allo-HSCT in MDS.•The composite endpoint of survival without relapse and without chronic GVHD was superior in the CD34+ cell-selected group.•Relapse is affected by high-risk cytogenetics, but not by type of transplant. In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS) who received a CD34+ cell-selected and those who received an unmodified allograft. This analysis initially included 181 patients, 60 who received a CD34+ cell-selected transplant and 121 who received an unmodified transplant. Owing to significant differences in disease characteristics, the analysis was limited to patients with
ISSN:	1083-8791 1523-6536
DOI:	10.1016/j.bbmt.2018.01.001